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We test the hypothesis that PARP inhibition can decrease acute tubular necrosis (ATN) and other renal lesions related to prolonged
cold ischemia/reperfusion (IR) in kidneys preserved at 4∘C in University of Wisconsin (UW) solution.Material and Methods. We
used 30male Parp1+/+ wild-type and 15male Parp10/0 knockout C57BL/6mice. Fifteen of these wild-typemice were pretreated with
3,4-dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ) at a concentration of 15mg/kg body weight, used as PARP
inhibitor. Subgroups of mice were established (A: IR 45min/6 h; B: IR + 48 h in UW solution; and C: IR + 48 h in UW solution
plus DPQ).We processed samples for morphological, immunohistochemical, ultrastructural, and western-blotting studies. Results.
Prolonged cold ischemia time inUWsolution increased PARP-1 expression and kidney injury. Preconditioningwith PARP inhibitor
DPQ plus DPQ supplementation in UW solution decreased PARP-1 nuclear expression in renal tubules and renal damage. Parp10/0
knockout mice were more resistant to IR-induced renal lesion. In conclusion, PARP inhibition attenuates ATN and other IR-related
renal lesions inmouse kidneys under prolonged cold storage in UW solution. If confirmed, these data suggest that pharmacological
manipulation of PARP activity may have salutary effects in cold-stored organs at transplantation.
1. Introduction
Until now, renal ischemia-reperfusion (IR) injury has been
inevitable in transplantation, resulting in the cell death
of renal tubular epithelial cells. Human kidneys retrieved
from cadaver donors for transplantation are perfused and
preserved in order to attenuate ischemic injury between the
harvesting of the organ and its transplantation. Currently,
the most effective preservation strategy to reduce ischemic
injury during prolonged cold storage is to decrease renal
oxygen demand by using both hypothermia and preservation
solutions (University of Wisconsin (UW) solution) together.
These solutions contain adenosine and impermeable saccha-
rides to prevent ATP precursor depletion and cell swelling,
respectively. However, this strategy is not sufficiently effective
to prevent preservation injury of the tissue [1, 2].
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Acute tubular necrosis (ATN) induced by IR injury
contributes to the development of delayed graft function
(DGF), which remains an important complication of kidney
transplantation and, despite advances in cold storage, is a
major risk factor for acute rejection and long-term kidney
allograft dysfunction [3]. Organ preservation solutions play
an important role in the prevention of DGF, especially
in organs from expanded criteria donors or exposed to
prolonged cold ischemia. [4].
The nuclear protein poly(ADP-ribose) polymerase-1
(PARP-1) is a 116 kDa protein member of PARP enzyme
family comprised of three functional domains. The amino-
terminal DNA-binding domain contains two zinc fingers that
are important for the binding of PARP-1 to single-strand
breaks and double-strand breaks [5, 6] and, especially, for the
detection of DNA breaks by genotoxic and oxygen-derived
free radicals. A third zinc finger is important for coupling
damage-induced changes in the DNA-binding domain to
alterations in PARP-1 catalytic activity [7–9]. PARP-1, known
to play a role as DNA damage sensor and in different DNA
repair pathways, was recently implicated in a wide variety of
cellular functions, including the regulation of transcription
[10]. IR injury produces excessive PARP-1 activation (see
review ofVirág and Szabó, 2002) [11], leading to nicotinamide
adenine dinucleotide (NAD+) and ATP depletion, which
produce various types ofDNAdamage [12, 13] that potentially
contribute to a type of metabolic cell death designated parth-
anatos [14]. In a previous study of humanbiopsies, we demon-
strated that PARP-1 expression was significantly related to
cold ischemia time, time to effective diuresis, serum creati-
nine levels, and degree of ATN [15].
The objective of the present study in mice was to test the
hypothesis that PARP inhibition can reduce ATN and other
renal lesions associated with prolonged cold IR in kidneys
preserved in UW solution, thereby improving the structural
preservation of renal grafts.
2. Material and Methods
2.1. IR Mouse Model. We used 30 male Parp1+/+ wild-type
(groups 1 and 2) and 15 male Parp10/0 knockout (group 3)
C57BL/6mice (24 wks old and 20–30 g). Knockoutmice were
obtained according to a previously reported procedure [16].
We kept the mice under stable conditions with ad libitum
access to food and water. All experiments were performed in
a homologated laboratory according to the European Union
and Spanish Government guidelines for the ethical care of
animals (EU Directive 86/609, RD 223/1988).
Mice were anesthetized by intraperitoneal inoculation of
equitensin (2 IU/20 g) and maintained at 37∘C on a thermal
plate.The left kidneywas accessed by anterolateral abdominal
horizontal incision of 1.5 cm, and the vascular pedicle was
clamped under surgical stereo microscope with a model 2A
S&Tmetallic clip (S&TMicrolabAG, Rheinfall, Switzerland),
maintaining the kidneys within the abdominal cavity under
UW solution flow at 4∘C. After 45min of clamping, the clip
was removed and the peritoneum and skin were sutured.
After 6 h of reperfusion, the animals were killed with an
overdose of sodium pentothal and perfused with cold UW
solution by intracardiac injection.Three animals died during
postoperative or reperfusion periods and were replaced.
2.2. Administration of PARP Inhibitor to Mice. The PARP
inhibitor 3,4-dihydro-5-[4-(1-piperidinyl) butoxyl]-1(2H)-
isoquinolinone (DPQ) was purchased from Alexis Biochem-
icals Corporation (Thermo Fisher Scientific, Waltham, MA)
and dissolved in dimethyl sulfoxide (DMSO) at a concen-
tration of 15mg/kg body weight. DPQ was administered
intraperitoneally at 24 h before ischemic injury (as precon-
ditioning) in group 1. Preliminary control experiments had
shown that administration of DPQ to sham-operated mice
had no morphological effects (data not shown).
2.3. Renal Samples and Processing. Three subgroups (𝑛 = 5
each) of left kidneys from C57BL/6 Parp1+/+ and C57BL/6
Parp10/0micewere established (A: IR 45min/6 h immediately
followed by euthanasia; B: IR 45min/6 h then followed by
48 h immersion at 4∘C in UW solution; and C: IR 45min/6 h
then followed by 48 h immersion at 4∘C in UW solution
plus DPQ (15mg/mL)). The right kidneys served as controls
(Parp1+/+ 𝑛 = 30; Parp10/0 𝑛 = 15). Postextraction, each
kidney sample was divided transversally into two halves.
One half, with cortex and medulla, was rapidly frozen in
isopentane at −50∘C and immersed in liquid nitrogen for 10 s
to develop western blotting. The other half was immediately
fixed in 10% buffered formalin for 24 h and then paraffin-
embedded for morphological study using hematoxylin-eosin
and PAS staining, which was done in blinded fashion on
4-micrometer sections with light microscopy. The presence
of acute necrosis, sloughing, and vacuolization of tubular
cells was calculated semiquantitatively on a 4-point scale (0,
absence; 1,mild (<10%of tubules involved); 2,moderate (10 to
25%); 3, severe (>25%)). The other variables (vascular lesion,
glomerular lesion, altered/lost brush border, and tubular cast)
were dichotomous (presence/absence).
2.4. Immunohistochemical Analysis. Nuclear expression of
PARP-1 was characterized by incubating sections for 30min
at room temperature with PARP-1 monoclonal antibody
(clone A6.4.12; Thermo Fisher, Fremont, CA, USA). The
immunochemistry study used an automatic immunostainer
(model autostainer480, Thermo Fisher) according to the
polymer peroxidase-based method, followed by develop-
ment with diaminobenzidine (Master Diagnóstica, Granada,
Spain). The positivity of immunostaining was calculated
semiquantitatively on a 4-point scale (0, absence; 1 (1–9% of
tubular nuclei positive); 2 (10–49%); 3 (≥50%)). In addition,
a millimeter scale in the eyepiece of a BH2 microscope
(Olympus Optical Company Ltd, Tokyo, Japan) with ×40
objective was used to count positive nuclei of cortical tubular
cells/mm2. Results were expressed as positive cells/mm2.
Renal sections incubated with isotype antibody were used as
negative controls.
2.5. Western Blotting. Western blotting was performed
according to previously published methods [17]. Tissues
extracted from the mice kidneys were washed with PBS


































































































Figure 1: Comparison of PARP-1 expression and kidney lesions between C57BL/6 mouse subgroups (A, B, and C). Red line: Parp1+/+ and
DPQ (i.p.), group 1. Blue line: Parp1+/+ wild-type, group 2. Green line: Parp10/0, group 3. ATN: acute tubular necrosis. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01
Kruskal Wallis test.
and resuspended in 100 𝜇L lysis buffer (50mM Tris-HCl
pH 8, 0.1mM EDTA, 0.5% Triton X-100, 12.5mM 𝛽-
mercaptoethanol) for 30min on ice. Pellet was eliminated
and sample buffer (50mM Tris-HCl pH 6.8, 6M urea, 6%
𝛽-mercaptoethanol, 3% SDS, 0.003% bromophenol blue)
was added to the supernatant. Proteins were resolved on
SDS- 12% polyacrylamide gels and transferred onto Immun-
Blot PVDF Membrane (Bio-Rad, Laboratories Irvine, CA).
The blot was blocked with 5% milk powder in PBS with
0.1% Tween-20 for 30min, washed with PBS/Tween, and
incubated overnight with anti-poly (ADPribose) (PAR)
(TREVIGEN, Gaithersburg, MD), anti-PARP-1 (clone C2-10)
(Alexis, San Diego, CA, USA), and anti-𝛼-tubulin (Sigma,
St Louis MO, USA) antibodies for 2 h with appropri-
ate secondary antibodies. Bands were visualized by ECL-
PLUS (Amersham Biosciences, Piscataways, NJ), and pho-
tographswere takenwith theChemiDocXRS imaging system
(Bio-Rad).
2.6. Electron Microscopy. Several 1mm2 fragments of kidney
cortex from each animal were fixed in 2.5% glutaraldehyde
solution and then postfixed in 1%OsO
4
at 4∘C for 2 h, washed
in distilled water, dehydrated in increasing concentrations
of acetone, and embedded in Epon following a conventional
protocol. Semithin sections were stained with toluidine blue
solution. Ten blocks of LC cluster areas were sampled. Ultra-
thin (∼70 nm-thick) sections were obtained in a Reichert
JungULTRACUTultramicrotome (Leica,Westlar, Germany)
and stained with lead citrate and uranyl acetate. Ultrathin
sections were examined under a Zeiss EM 902 transmission
electron microscope and processed using analysis software
for Windows (Soft Imaging System, Münstes, Germany).
2.7. Statistical Analysis. A descriptive analysis was per-
formed, and the Mann-Whitney 𝑈-test and Kruskal Wallis
test were applied to determine statistical significances. SPSS-
Windows 20.0 (IBMSPSS Inc, Chicago, IL, USA)was used for
data analyses. The confidence interval was 95% (𝑃 < 0.05).
3. Results
3.1. Histopathological Kidney Lesions. Control kidney tissue
sections had a normal morphology, with no evident struc-
tural changes in tubules, vessels, or glomeruli (Table 1). IR-
exposed kidneys showed distinctive patterns of ischemia
renal injury that varied in severity among the groups
(Figure 1), including widespread degeneration of tubular
architecture, alteration/loss of brush border, sloughing of
tubular epithelial cells frombasementmembrane, scant tubu-
lar vacuolization, tubular cell necrosis, and intratubular cast
formation in the outer medulla (including proximal tubule
S3 segment and thick ascending limb). Ultrastructurally,
we observed moderate vacuolization of proximal convo-
luted tubular cells with cytoplasmatic edema and intense
injury to endothelial cells in renal peritubular capillaries
(Figure 2). Table 1 summarizes the results of comparing
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Figure 2: Morphological kidney injury after ischemia/reperfusion (IR) in different groups and subgroups of C56BL/6 mice. (PAS, original
magnification 20x). Note loss of brush border and increased acute tubular necrosis in Parp1+/+ mouse kidney (IR + 48 h UW subgroup) but
only tubular vacuolization in Parp1+/+ mouse kidney (IR + 48 h UW&DPQ subgroup). Kidney structure was preserved in all subgroups of
Parp10/0 and in Parp1+/+ wild-type mice pretreated with ip DPQ. Ultrastructural study confirms higher tubular injury in kidneys immersed
for 48 h at 4∘C in University ofWisconsin (UW) solution (asterisk). Arrows indicate endothelial cell injury in peritubular capillaries (original
magnification ×4600).
histopathological variables among the groups (3 groups of IR
kidneys and controls).
3.2. Prolonged Cold Ischemia Time in UW Solution Increases
PARP-1 Expression and Kidney Injury. ATN, sloughing of
tubular cells, alteration/loss of brush border, and tubular casts
were significantly more evident in kidneys immersed for 48 h
in WU (Figures 1 and 2). These lesions were related to higher
PARP-1 expression by immunohistochemistry (Figure 3) and
to higher PARP expression and greater kidney protein ribo-
sylation by western blotting (Figure 4).
3.3. Preconditioning with PARP Inhibitor DPQ Plus DPQ
Supplementation in UW Solution Reduces PARP-1 Nuclear
Expression in Renal Tubules. Treatment with i.p. DPQ at 24 h
before IR significantly reduced tubular PARP-1 expression,
tubular injury (ATN and vacuolization), and the number
of animals affected. Kidneys from DPQ-treated animals




























Group 1 Group 2 Group 3
C57BL/6 Parp1+/+ C57BL/6 Parp1+/+ C57BL/6 Parp10/0
Figure 3: Modification in mouse kidney tubular PARP-1 expression. Kidneys immersed for 48 h at 4∘C in UW induces nuclear PARP-1
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Figure 4: Protein ribosylation was increased in IR kidneys immersed for 48 h at 4∘C in UW without DPQ PARP-1 inhibitor; this increase
was smaller in subgroups without pretreatment (line 8, group 2) and smallest in IR kidneys immersed for 48 h at 4∘C in UW with DPQ
supplementation (line 8, group 1).
preserved in UW solution plus DPQ evidenced a greater
reduction in PARP-1 expression and tubular injury, finding no
significant differences with their respective controls (Table 1
and Figure 1). A reduction in protein ribosylation was also
detected by western blotting (Figure 4). The presence of
DPQ inWU solution alone (without DPQ pretreatment) also
produced a significant decrease in PARP-1 expression and
tubular lesions (Figure 3).
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3.4. Parp10/0 Knockout Mice are More Resistant to IR-Induced
Renal Lesion. The absence of PARP-1 significantly reduced
IR-induced tubular lesions, finding scant histopathological
alterations and no significant differences with the changes
observed in control kidneys (Table 1).
4. Discussion
Themain finding of this study was that the administration of
PARP inhibitor DPQ to kidneys and its addition to the UW
solution in which they are cold-stored attenuated ATN and
other IR-related lesions. These results, if confirmed, would
indicate that the pharmacological manipulation of PARP
activity may exert salutary effects in clinical settings in which
reperfusion injury is problematic, as in cold-stored organs at
transplantation.
After cellular exposure to genotoxic agents in IR injury,
the genome integrity of PARP is maintained, but extensive
DNA damage may lead to excessive PARP activation, which
consumes large quantities of cellular NAD, producing ATP
depletion and cell death [18]. Therefore, although chronic
inhibition of PARP activity is likely to be harmful to cells, it
has been proposed that its transient inhibition after IR injury
may prevent cell death [19].
Tissue ischemia and reperfusion result in activation of
the nuclear enzyme PARP. This enzyme is activated 500-
fold by single-strand DNA breaks and cleaves NAD+ to
attach ADP-ribose polymers to proteins associated with the
damaged DNA [20, 21]. Hypoxia due to decreased blood flow
leads to a breakdown in cellular energy metabolism and can
generate reactive oxygen species (ROS) and reactive nitrogen
species [18, 19, 22]. However, our finding of increased PARP-1
expression and activation of protein poly(ADP-ribosyl)ation
during cold storage without reperfusion implies that PARP is
also activated by other agents besides ROS during the time
interval between organ harvesting and transplantation. In a
previous immunohistochemistry study by our group, all 20
kidneys were ruled out for transplantation but preserved as
whole perfused kidneys that showed a marked increase in
PARP-1 expression between the biopsy at 0 h and the renal
cortex after 48 h of cold ischemia in UW solution, when a
mild activation of PARP-1 was evidenced by western blotting
results [15].
Numerous studies have demonstrated a significant role
for PARP in reperfusion injury in a variety of tissues,
organs, and models. Early investigations demonstrated that
chemically distinct inhibitors of PARP activity such as ben-
zamides and isoquinolinones can reduce the degree of injury
associated with IR of different organs [22–28], providing the
basis for potential clinical applications of PARP inhibitors
[29]. Furthermore, the degree of tissue injury caused by IR
is attenuated in Parp knockout mice [30].
Isoquinolinones such as DPQ, 1,5-DHIQ [1,5-dihydr-
oxyisoquinoline (5-hydroxyisoquinolin-1(2H)-one)], PJ-34
(phenanthridinone-based PARP inhibitor), INO-1001 (ind-
eno isoquinolinone), and FR247304 are potent PARP inhi-
bitors [30] but are only soluble in solvents such as dimethyl-
sulfoxide (DMSO), which is itself a potent scavenger of
hydroxyl radicals and inhibits PARP activity [31]. This
explains why DMSO per se can reduce IR-related kidney
injury [32, 33] without, at the low concentration used,
inducing morphological changes.
The lesions observed in this murine IRmodel correspond
to incipient ATN alterations. Their relationship with Parp
overactivation is evidenced by the few renal parenchymatous
lesions in PARP-10/0 mice and by the reduction in lesions
and increase in protein poly(ADP-ribosyl)ation after DPQ
administration in parp1+/+ wild-type mice. Chatterjee pre-
viously reported that PARP activation contributes in part to
postreperfusion renal dysfunction and damage to renal tissue
with previous ischemia, based on the following experimental
evidence: (1) an increased immunohistochemical expression
of PARP after renal IR, (2) a significant improvement in
renal alterations (reduced urea and creatinine levels and
increased glomerular filtrate) with the use of benzamide
analogs, selective PARP inhibitors, (3) the lack of effect on
IR-induced renal dysfunction of aminobenzoic and nicotinic
acids, which do not inhibit PARP [34], and (4) protection
by PARP inhibitors of primary cultures of rat proximal
kidney tubules against lesion and oxidative stress-mediated
cell death [35]. Further research is warranted to confirm our
finding of a reduction in renal lesions when DPG is used for
preconditioning and also added to the WU solution, which
may represent a new strategy to avoid damage during the cold
storage of renal grafts.
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